The molecular subtype was another significant consideration, and women with HER2-positive or triple-negative tumours were four times more likely to be recommended chemotherapy compared to women with hormone-responsive HER2-negative tumours (p < 0.001, OR 0.268, 95% CI 0.184–0.391). The gene discussed is ERBB2; the disease is neoplasm.